MedImmune maintained by Merrill Lynch at neutral

MedImmune Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating following its amended marketing agreement for Synagis with Abbott Laboratories. MedImmune shares Wednesday were down $0.20, or 0.67%, at $29.73 on volume of 5,935,425 shares versus the three-month running average of 1,717,220 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.